She changed the culture of NAFDAC to Customer-focused and Agency-minded establishment in order to safeguard the health of the nation. All these have resulted in attainment of ISO 9001-2015 in 2019, yearly re-certification, and WHO Maturity Level 3 (ISO 9004) in 2022, a recognition as a well-functioning Agency.  

Consequent to these is the gradual strengthening of the pharmaceutical industry as exemplified in the recent WHO prequalification of a pediatric product of a local manufacturer, the first in West and Central Africa. The paradigm shift for access to medicines included the introduction of innovative reforms such as the 5+5 policy, the expansion of NAFDAC’s ceiling list to thirty-four (34) products (aimed at increasing access to quality medicine through local manufacturing), new policy on establishment of Pharmaceutical Plants in Nigeria, the centralized GMP inspection for Pharma plants and Good Distribution Practice (GDP) inspection. 

The ongoing transformative leadership is reflective in the strengthening of grassroot pharmacovigilance or post-marketing safety monitoring, expansion of risk-based post marketing surveillance,  introduction of Dossier Management System (an online solution that streamlines the dossier), leading in Africa the development and use of Traceability Information System – a GS1-driven technology – to give COVID-19 vaccines and ATM commodities’ supply chain visibility and mitigate substandard and falsified medicines, as part of restructuring toward  ML4 and WLA status. 

She leads the Agency in strengthening of the Food industry in the Agency through emphasis on Food Safety, evidence-based Chemicals and Pesticides Management.  

She inaugurated Nigerian Herbal Medicine Product Committee (HMPC) as a means of fostering research involving herbal practitioners and academic researchers while the intellectual property is protected. The ultimate goal is to turn complementary alternative medicines into a research-driven, regulation controlled commercially viable commodities.

She is the past Chair of the Steering Committee of the African Medicines Regulatory Harmonization (AMRH) and the WHO-based Global Pediatric Regulatory Network. She represents NAFDAC on the International Coalition of Medicines Regulatory Authorities (ICMRA) and has been invited to be on the WHO Regional Expert Advisory Committee on Traditional Medicine for COVID-19.   

She is a Fellow of Nigeria Academy of Science, Nigeria Academy of Pharmacy, an Academic Research Fellow of American Association of Colleges of Pharmacy (AACP). 

She is the First African Woman Fellow, American Association of Pharmaceutical Scientists (AAPS) a society where only 3% of academia receives such recognition internationally.

She is Professor Emeritus of Pharmaceutics and Drug Product Evaluation at the College of Pharmacy, Roosevelt University in Schaumburg, Illinois, USA.  Professor Adeyeye was the founding Chair of Biopharmaceutical Sciences at the same University in Illinois. 

She was Professor of Pharmaceutics and Manufacturing for twenty-one (21) years at Duquesne University in Pittsburgh, PA, USA.   She is a Senior Fulbright Scholar and Specialist. 

She earned her B.S from the University of Nigeria, Nsukka, Nigeria and MS and PhD from the University of Georgia, Athens, GA. Her research interests include quality-by-design (QbD) early phase development and manufacturing of solid, semisolid and liquid dosage forms, including Investigation New Drug Application (IND)-based late phase manufacturing.  

She is an expert in research and drug development (R&D), bench-to-bedside translational research and regulatory science. She has mentored over 15 PhD and M.S candidates. She has 5 patents, 65 peer reviewed manuscripts, book chapters and books, and more than 160 scientific presentations.